Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMB-100 with or without nab-paclitaxel in malignant mesothelioma
NCT02798536Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2016
- Primary completion
- Jul 2017
- Modality
- Antibody-Drug Conjugates (ADCs), Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of LMB-100 in mesothelioma (4 arms), sponsored by National Cancer Institute. Primary endpoint: Recommended Phase 2 Dose at 3 weeks. Started Jul 2016; status: completed.
02
Drugs
LMB-100
03
Conditions
mesothelioma
Beyond the preview
Go deeper on NCT02798536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02798536.